1. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation. (October 2020) Authors: Jänne, P.A.; Rybkin, I.I.; Spira, A.I.; Riely, G.J.; Papadopoulos, K.P.; Sabari, J.K.; Johnson, M.L.; Heist, R.S.; Bazhenova, L.; Barve, M.; Pacheco, J.M.; Leal, T.A.; Velastegui, K.; Cornelius, C.; Olson, P.; Christensen, J.G.; Kheoh, T.; Chao, R.C.; Ou, S.H.I. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation. (October 2020) Authors: Johnson, M.L.; Ou, S.H.I.; Barve, M.; Rybkin, I.I.; Papadopoulos, K.P.; Leal, T.A.; Velastegui, K.; Christensen, J.G.; Kheoh, T.; Chao, R.C.; Weiss, J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗